In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
A novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 m...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2000
|
| _version_ | 1826275543897604096 |
|---|---|
| author | Kottaridis, P Milligan, D Chopra, R Chakraverty, R Chakrabarti, S Robinson, S Peggs, K Verfuerth, S Pettengell, R Marsh, J Schey, S Mahendra, P Morgan, G Hale, G Waldmann, H Elvira, d Williams, C Devereux, S Linch, D Goldstone, A Mackinnon, S |
| author_facet | Kottaridis, P Milligan, D Chopra, R Chakraverty, R Chakrabarti, S Robinson, S Peggs, K Verfuerth, S Pettengell, R Marsh, J Schey, S Mahendra, P Morgan, G Hale, G Waldmann, H Elvira, d Williams, C Devereux, S Linch, D Goldstone, A Mackinnon, S |
| author_sort | Kottaridis, P |
| collection | OXFORD |
| description | A novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 mg/day on days -8 to -4; fludarabine, 30 mg/m(2) on days -7 to -3; and melphalan, 140 mg/m(2) on day -2. Thirty-six recipients received unmanipulated granculocyte colony-stimulating factor-mobilized peripheral blood stem cells from HLA-identical siblings, and 8 received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporine A alone for 38 patients and cyclosporine A plus methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete remission or with no evidence of disease progression. Seven patients relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were no cases of grades III-IV acute GVHD. Only 2 patients developed grade II acute GVHD, and only 1 had chronic GVHD. The estimated probability of nonrelapse mortality was 11%. Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD. |
| first_indexed | 2024-03-06T23:00:19Z |
| format | Journal article |
| id | oxford-uuid:61e2e5ff-cc83-4a4b-8cfa-7f25eb2ea796 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:00:19Z |
| publishDate | 2000 |
| record_format | dspace |
| spelling | oxford-uuid:61e2e5ff-cc83-4a4b-8cfa-7f25eb2ea7962022-03-26T18:02:47ZIn vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:61e2e5ff-cc83-4a4b-8cfa-7f25eb2ea796EnglishSymplectic Elements at Oxford2000Kottaridis, PMilligan, DChopra, RChakraverty, RChakrabarti, SRobinson, SPeggs, KVerfuerth, SPettengell, RMarsh, JSchey, SMahendra, PMorgan, GHale, GWaldmann, HElvira, dWilliams, CDevereux, SLinch, DGoldstone, AMackinnon, SA novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 mg/day on days -8 to -4; fludarabine, 30 mg/m(2) on days -7 to -3; and melphalan, 140 mg/m(2) on day -2. Thirty-six recipients received unmanipulated granculocyte colony-stimulating factor-mobilized peripheral blood stem cells from HLA-identical siblings, and 8 received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporine A alone for 38 patients and cyclosporine A plus methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete remission or with no evidence of disease progression. Seven patients relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were no cases of grades III-IV acute GVHD. Only 2 patients developed grade II acute GVHD, and only 1 had chronic GVHD. The estimated probability of nonrelapse mortality was 11%. Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD. |
| spellingShingle | Kottaridis, P Milligan, D Chopra, R Chakraverty, R Chakrabarti, S Robinson, S Peggs, K Verfuerth, S Pettengell, R Marsh, J Schey, S Mahendra, P Morgan, G Hale, G Waldmann, H Elvira, d Williams, C Devereux, S Linch, D Goldstone, A Mackinnon, S In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. |
| title | In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. |
| title_full | In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. |
| title_fullStr | In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. |
| title_full_unstemmed | In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. |
| title_short | In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. |
| title_sort | in vivo campath 1h prevents graft versus host disease following nonmyeloablative stem cell transplantation |
| work_keys_str_mv | AT kottaridisp invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT milligand invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT choprar invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT chakravertyr invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT chakrabartis invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT robinsons invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT peggsk invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT verfuerths invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT pettengellr invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT marshj invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT scheys invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT mahendrap invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT morgang invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT haleg invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT waldmannh invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT elvirad invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT williamsc invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT devereuxs invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT linchd invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT goldstonea invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation AT mackinnons invivocampath1hpreventsgraftversushostdiseasefollowingnonmyeloablativestemcelltransplantation |